Emerging Longevity Ventures

Emerging Longevity Ventures is a venture capital firm founded in 2017 and based in West Palm Beach, Florida. The firm focuses on investing in the pharmaceutical sector, aiming to support innovative companies that contribute to advancements in longevity and health. As a principal investment firm, it seeks to identify and nurture opportunities that align with its mission to enhance the quality of life through strategic investments in emerging technologies and solutions in healthcare.

Brian Delaney

Founder and Scientific Analyst

Allan Weiner

Investment Director

4 past transactions

Senisca

Venture Round in 2024
Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Senisca

Seed Round in 2022
Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Senisca

Seed Round in 2021
Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Repair Biotechnologies

Seed Round in 2019
Repair Biotechnologies, Inc. is a biotechnology company focused on developing innovative treatments aimed at reversing immunosenescence and atherosclerosis associated with aging. Founded in 2018 and based in Syracuse, New York, the company utilizes a cholesterol-degrading platform to create therapies that target conditions driven by excess or modified cholesterol, such as atherosclerosis and familial hypercholesterolemias. Through its gene therapy and recombinant protein approaches, Repair Biotechnologies seeks to address significant age-related health issues by treating the underlying causes of these medical conditions. The company's emphasis on safety and tolerability enhances its commitment to improving patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.